Treatment With Copper in Patients With Mild Alzheimer´s Dementia

Status Completed

Clinical Trial Summary

The efficacy of 8 mg of copper daily regarding cognitive function, content of beta amyloid protein in the CSF and volumetric changes in the brain will be examined in a first double-blind, placebo-controlled human clinical trial conducted in 70 patients with mild Alzheimer´s dementia.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00608946
Study type	Interventional
Source	University Hospital, Saarland
Contact
Status	Completed
Phase	Phase 2
Start date	March 2004

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT02245737` - An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease	Phase 2/Phase 3
Completed	`NCT02360527` - Retinal Neurodegeneration in Type 2 Diabetes as Biomarker for Alzheimer´s Disease	N/A
Completed	`NCT01225809` - AD01 Follow up Extension Visit	N/A
Terminated	`NCT01117948` - Efficacy and Safety of Lornoxicam in Patients With Mild to Moderate Probable Alzheimer´s Disease.	Phase 2
Terminated	`NCT01736579` - Long-Term Study of IGIV, 10% in Alzheimer´s Disease	Phase 3
Completed	`NCT02501876` - Type 2 Diabetes Mellitus as Catalyst for Alzheimer's Disease	N/A
Active, not recruiting	`NCT01695889` - Is There a Relationship Between Previous Exposure to General Anesthesia and the Development of Alzheimer´s Disease?	N/A
Terminated	`NCT02008513` - Follow-up Study to Assess Safety and Clinical Activity of Continued AFFITOPE® AD02 Vaccinations of Patients Who Participated in AFF006	Phase 2
Completed	`NCT02224326` - Vagus Somatosensory Evoked Potentials and Near-infrared Spectroscopy in the Early Diagnosis of Dementia
Terminated	`NCT01125683` - To Evaluate Effects of AZD1446, Placebo and Donepezil in Patients With Alzheimer's Disease	Phase 2
Terminated	`NCT01357629` - Observational Follow-up Extension Study of AFF002 and AFF004A in Patients With Alzheimer's Disease	N/A
Terminated	`NCT01524887` - Phase 3 IGIV, 10% in Alzheimer´s Disease	Phase 3
Completed	`NCT00692705` - Positron Emission Tomography (PET) Study With [11C]AZD2995 and [11C]AZD2184, Candidate PET Ligands for β Amyloid	Phase 1
Active, not recruiting	`NCT02623764` - EEG-cholinergic Index and Clinical Response to Treatment With Cholinesterase Inhibitors
Completed	`NCT00948259` - Safety Study of a Glycogen Synthase Kinase 3 (GSK3) Inhibitor in Patients With Alzheimer´s Disease	Phase 1/Phase 2
Completed	`NCT00818662` - A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild-to-Moderate Alzheimer´s Disease	Phase 3